Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans.
Transcutaneous immunisation (TCI) using a skin patch is a non-invasive vaccination route relevant to mass vaccination against infectious diseases. This phase I/II clinical study, documents that TCI of human adult volunteers with the live-attenuated measles vaccine ROUVAX((R)) is safe and poorly reactogenic. It promotes induction of measles-specific salivary IgA and a tendency to increased frequency of MV-specific IFNgamma-producing T cells. However, in contrast to the subcutaneous route, TCI failed to evoke neutralising MV-specific serum antibodies. Thus, alternative delivery methods and/or devices providing optimal uptake by skin DC should be considered for live-attenuated virus vaccines, such as the measles vaccine.
Etchart
Nathalie
N
INSERM U404, Lyon F-69007, France; Université Lyon 1, Lyon F-69003, France; IFR128, Lyon F-69007, France.
Hennino
Ana
A
Friede
Martin
M
Dahel
Karima
K
Dupouy
Monique
M
Goujon-Henry
Catherine
C
Nicolas
Jean-François
JF
Kaiserlian
Dominique
D
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000818:Animals; D002522:Chlorocebus aethiops; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007371:Interferon-gamma / Q000096:biosynthesis; D008457:Measles / Q000517:prevention & control*; D008458:Measles Vaccine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008459:Measles virus / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014709:Vero Cells
D007071:Immunoglobulin A, Secretory; D008458:Measles Vaccine; D014613:Vaccines, Attenuated; D007371:Interferon-gamma